Concepedia

Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France

Ronan Roussel, L. Martínez, T. Vandebrouck, Habiba Douik, Patrick Emiel, Matthieu Guéry, Barnaby Hunt, William J. Valentine

Journal of Medical Economics · 2015 · 21 citations · 33 references

DOI

Abstract

Calculated ICERs for both comparisons fell below the commonly quoted willingness-to-pay threshold of €30,000 per QALY gained. Therefore, liraglutide is likely to be cost-effective vs sitagliptin and glimepiride from a healthcare payer perspective in France.

References

33

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 19.9K citations

, , +9

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +10

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.6K citations · Full text

Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes

Peter Gæde, Pernille Vedel, Nicolai Balle Larsen et al. · New England Journal of Medicine · 2003 · 4.4K citations · Full text

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

David M. Nathan, John B. Buse, Mayer B. Davidson et al. · Diabetes Care · 2008 · 3.8K citations · Full text

, , +14